Hims & Hers in talks with Novo Nordisk over Wegovy return
Less than six months after ending a short-lived partnership, US telehealth firm Hims & Hers (Nasdaq: HIMS) and Danish drugmaker Novo Nordisk (NOV: N) are in active discussions over a renewed deal for Wegovy (semaglutide). The move could see both the injectable formulation and Novo’s forthcoming oral obesity pill made available via the Hims & Hers platform, pending US approval.
Hims & Hers said talks are ongoing and no agreement has been signed. The company added there is a possibility discussions may not lead to a deal, and if one is reached, its terms could differ from what is currently anticipated. Chief executive Andrew Dudum told investors he was “excited to re-engage with Novo,” but declined to elaborate on the negotiations.
Analysts at Leerink Partners suggested a potential partnership could bolster Hims & Hers’ weight-loss business and ease concerns over its ability to distribute obesity drugs. The company’s stock rose 6% in after-hours trading following the announcement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze